Gastrointestinal

• SRRM2 drives colorectal cancer growth by a dual mTOR regulation

  Cancer

  Scientists at Southern University of Science and Technology in Shenzhen, China, have identified a new regulator of the mammalian target of rapamycin (mTOR) pathway associated with the growth of colorectal cancer.

• Glycopolymer radiomitigator protects mice from radiation-induced GI injury

  Substance use and poisoning

  Exposure to high-dose radiation can result in gastrointestinal (GI) acute radiation syndrome, which is characterized by disruption of the mucosal layer, intestinal epithelial barrier dysfunction, and abnormal inflammatory responses. Currently,...

• Synthetic microbiome prevents Clostridioides difficile recurrences

  Science

  Investigators at Pennsylvania State University have described a novel approach to combat Clostridioides difficile infection using a synthetic microbiome therapy, which offers an alternative to antibiotics and fecal microbiota transplant (FMT). C....

• IL-21120033, CXCR7 agonist with significant efficacy in DSS-induced colitis model

  Conferences

  Researchers from Ileadbms Co. Ltd. presented the discovery and preclinical characterization of IL-21120033, a new CXCR7 agonist being developed for the treatment of inflammatory bowel disease.

• Neurenati’s NEU-001 awarded orphan drug designation for Hirschsprung disease

  Regulatory

  Neurenati Therapeutics Inc.’s NEU-001 has been awarded U.S. orphan drug and rare pediatric disease designations by the FDA for the treatment of Hirschsprung disease.

• New microbiome-based therapy shows potent anti-inflammatory efficacy in models of IBD

  Conferences

  Researchers from CJ Bioscience Inc. presented the discovery and preclinical characterization of CJRB-201, a novel microbiome-based therapy for the treatment of inflammatory bowel disease (IBD).